Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 3/2016

01-06-2016 | Interpretive Synthesis Review Article

Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome

Authors: Yan-Mei Huang, Xue-Zhi Hong, Jia-Hua Xu, Jiang-Xi Luo, Han-You Mo, Hai-Lu Zhao

Published in: Immunologic Research | Issue 3/2016

Login to get access

Abstract

Acquired immunodeficiency syndrome (AIDS) remains ill-defined by lists of symptoms, infections, tumors, and disorders in metabolism and immunity. Low CD4 cell count, severe loss of body weight, pneumocystis pneumonia, and Kaposi’s sarcoma are the major disease indicators. Lines of evidence indicate that patients living with AIDS have both immunodeficiency and autoimmunity. Immunodeficiency is attributed to deficits in the skin- and mucosa-defined innate immunity, CD4 T cells and regulatory T cells, presumably relating human immunodeficiency virus (HIV) infection. The autoimmunity in AIDS is evident by: (1) overproduction of autoantibodies, (2) impaired response of CD4 cells and CD8 cells, (3) failure of clinical trials of HIV vaccines, and (4) therapeutic benefits of immunosuppression following solid organ transplantation and bone marrow transplantation in patients at risk of AIDS. Autoantibodies are generated in response to antigens such as debris and molecules de novo released from dead cells, infectious agents, and catabolic events. Disturbances in metabolic homeostasis occur at the interface of immunodeficiency and autoimmunity in the development of AIDS. Optimal treatments favor therapeutics targeting on the regulation of metabolism to restore immune homeostasis.
Literature
1.
Centers for Disease Control. Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250–2.
2.
Centers for Disease Control. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep. 1981;30(25):305–8.
3.
4.
Fainstein V, Bolivar R, Mavligit G, Rios A, Luna M. Disseminated infection due to Mycobacterium avium-intracellulare in a homosexual man with Kaposi’s sarcoma. J Infect Dis. 1982;145(4):586.PubMedCrossRef
5.
Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425–31. doi:10.​1056/​NEJM198112103052​401.PubMedCrossRef
6.
Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–8. doi:10.​1056/​NEJM198112103052​402.PubMedCrossRef
7.
Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):865–7.PubMedCrossRef
8.
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868–71.PubMedCrossRef
9.
10.
Gelmann EP, Popovic M, Blayney D, Masur H, Sidhu G, Stahl RE, et al. Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS. Science. 1983;220(4599):862–5.PubMedCrossRef
11.
12.
Duesberg PH. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacol Ther. 1992;55(3):201–77.PubMedCrossRef
13.
14.
15.
16.
Centers for Disease Control. Current trends update on acquired immune deficiency syndrome (AIDS)—United States. MMWR Morb Mortal Wkly Rep. 1982;31(37):4.
17.
Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305(24):1439–44. doi:10.​1056/​NEJM198112103052​403.PubMedCrossRef
18.
19.
20.
21.
22.
23.
24.
Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy. AIDS. 2001;15(2):291–2.PubMedCrossRef
25.
Holland HK, Saral R, Rossi JJ, Donnenberg AD, Burns WH, Beschorner WE, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1989;111(12):973–81.PubMedCrossRef
26.
Contu L, La Nasa G, Arras M, Pizzati A, Vacca A, Carcassi C, et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant. 1993;12(6):669–71.PubMed
27.
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–65. doi:10.​1086/​428404.PubMedCrossRef
28.
Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis. 2005;192(6):974–83. doi:10.​1086/​432734.PubMedCrossRef
29.
Levine AM, Groshen S, Allen J, Munson KM, Carlo DJ, Daigle AE, et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(4):351–64.PubMedCrossRef
30.
Lifson JD, Rossio JL, Piatak M Jr, Bess J Jr, Chertova E, Schneider DK, et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retrovir. 2004;20(7):772–87. doi:10.​1089/​0889222041524661​.PubMedCrossRef
31.
Pion M, Jaramillo-Ruiz D, Martinez A, Munoz-Fernandez MA, Correa-Rocha R. HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS. 2013;27(13):2019–29. doi:10.​1097/​QAD.​0b013e32836253fd​.PubMedCrossRef
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193(11):1303–10.PubMedPubMedCentralCrossRef
43.
Mendez-Lagares G, Jaramillo-Ruiz D, Pion M, Leal M, Munoz-Fernandez MA, Pacheco YM, et al. HIV infection deregulates the balance between regulatory T cells and IL-2-producing CD4 T cells by decreasing the expression of the IL-2 receptor in Treg. J Acquir Immune Defic Syndr. 2014;65(3):278–82. doi:10.​1097/​QAI.​0000000000000092​.PubMedCrossRef
44.
Boelaert JR, Appelberg R, Gomes MS, Blasi E, Mazzolla R, Grosset J, et al. Experimental results on chloroquine and AIDS-related opportunistic infections. J Acquir Immune Defic Syndr. 2001;26(3):300–1.PubMedCrossRef
45.
46.
47.
48.
49.
50.
Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162(9):5317–26.PubMed
51.
52.
Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003;197(4):403–11.PubMedPubMedCentralCrossRef
53.
54.
55.
Edelman AS, Zolla-Pazner S. AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency. FASEB J. 1989;3(1):22–30.PubMed
56.
Lepe-Zuniga JL, Mansell PW. AIDS: from immunity to infection to autoimmunity. A comprehensive hypothesis of the pathogenesis of the disease. AIDS Res. 1986;2(4):363–8.PubMedCrossRef
57.
Kion TA, Hoffmann GW. Anti-HIV and anti-anti-MHC antibodies in alloimmune and autoimmune mice. Science. 1991;253(5024):1138–40.PubMedCrossRef
58.
Ziegler JL, Stites DP. Hypothesis: AIDS is an autoimmune disease directed at the immune system and triggered by a lymphotropic retrovirus. Clin Immunol Immunopathol. 1986;41(3):305–13.PubMedCrossRef
59.
60.
Klinman DM, Morse HC 3rd. Characteristics of B cell proliferation and activation in murine AIDS. J Immunol. 1989;142(4):1144–9.PubMed
61.
62.
63.
64.
65.
66.
67.
68.
Toso C, Berney T, Oberholzer J, Chave JP, Martin PY, Zeender E, et al. Kidney-pancreas transplantation in a long-term non-progressor HIV-infected recipient. Am J Transplant. 2003;3(5):631–3.PubMedCrossRef
69.
70.
71.
Jacobson SK, Calne RY, Wreghitt TG. Outcome of HIV infection in transplant patient on cyclosporin. Lancet. 1991;337(8744):794.PubMedCrossRef
72.
Schwarz A, Offermann G, Keller F, Bennhold I, L’Age-Stehr J, Krause PH, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and review of the literature. Transplantation. 1993;55(1):95–103.PubMedCrossRef
73.
Ahuja TS, Zingman B, Glicklich D. Long-term survival in an HIV-infected renal transplant recipient. Am J Nephrol. 1997;17(5):480–2.PubMedCrossRef
74.
75.
76.
77.
Verheyen J, Esser S, Kordelas L. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N Engl J Med. 2014;371(25):2438. doi:10.​1056/​NEJMc1412279.PubMed
78.
79.
80.
Henrich TJ, Hanhauser E, Sirignano MN, Kuritzkes DR. HIV-1 rebound following allogeneic stem cell transplantation and treatment interruption. In: 21st conference on retroviruses and opportunistic infections, Boston; 2014. p. 3–6.
81.
Henrich TJ, Hanhauser E, Li JZ, Heisey A, Abramson JS, Hamdan A, et al. Impact of systemic cytotoxic chemotherapy for malignancies on HIV-1 reservoir persistence. In: 21st conference on retroviruses and opportunistic infections, Boston; 2014.
82.
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194(12):1661–71. doi:10.​1086/​508748.PubMedCrossRef
83.
84.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20. doi:10.​1056/​NEJMoa0908492.PubMedCrossRef
85.
86.
87.
88.
89.
90.
91.
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507–15. doi:10.​1016/​S1473-3099(11)70098-6.PubMedPubMedCentralCrossRef
92.
93.
94.
Fauci AS. The syndrome of Kaposi’s sarcoma and opportunistic infections: an epidemiologically restricted disorder of immunoregulation. Ann Intern Med. 1982;96(6 Pt 1):777–9.PubMedCrossRef
95.
Acquired immunodeficiency syndrome. Lancet. 1983;1(8317):162–4.
96.
Giorgi JV, Nishanian PG, Schmid I, Hultin LE, Cheng HL, Detels R. Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection. J Clin Immunol. 1987;7(2):140–50.PubMedCrossRef
97.
Salazar-Gonzalez JF, Moody DJ, Giorgi JV, Martinez-Maza O, Mitsuyasu RT, Fahey JL. Reduced ecto-5′-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: evidence of CD8 cell immaturity. J Immunol. 1985;135(3):1778–85.PubMed
98.
99.
100.
Rawson PM, Molette C, Videtta M, Altieri L, Franceschini D, Donato T, et al. Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med. 2007;13(12):1431–9. doi:10.​1038/​nm1679.PubMedCrossRef
101.
102.
Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004;351(8):760–8. doi:10.​1056/​NEJMoa040085.PubMedCrossRef
103.
Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990;113(10):733–9.PubMedCrossRef
104.
Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis. 1995;172(3):648–55.PubMedCrossRef
105.
Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978–1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1994;7(3):279–86.PubMed
106.
Vojdani A. Molecular mimicry as a mechanism for food immune reactivities and autoimmunity. Altern Ther Health Med. 2015;21(Suppl. 1):34–45.PubMed
107.
108.
109.
110.
Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr. 1985;42(6):1255–65.PubMed
111.
Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50(3):444–7.PubMed
112.
113.
Colebunders R, Francis H, Mann JM, Bila KM, Izaley L, Kimputu L, et al. Persistent diarrhea, strongly associated with HIV infection in Kinshasa, Zaire. Am J Gastroenterol. 1987;82(9):859–64.PubMed
114.
Dworkin B, Wormser GP, Rosenthal WS, Heier SK, Braunstein M, Weiss L, et al. Gastrointestinal manifestations of the acquired immunodeficiency syndrome: a review of 22 cases. Am J Gastroenterol. 1985;80(10):774–8.PubMed
115.
Sepkowitz KA, Telzak EE, Carrow M, Armstrong D. Fever among outpatients with advanced human immunodeficiency virus infection. Arch Intern Med. 1993;153(16):1909–12.PubMedCrossRef
116.
Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al. Primary human immunodeficiency virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30(3):486–90. doi:10.​1086/​313718.PubMedCrossRef
117.
Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al. Diagnosis of primary HIV-1 infection. Los Angeles County primary HIV infection recruitment network. Ann Intern Med. 2001;134(1):25–9.PubMedCrossRef
118.
Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399–406.PubMedCrossRef
119.
120.
121.
122.
Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003;52(4):918–25.PubMedCrossRef
123.
124.
Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 1997;350(9091):1596.PubMedCrossRef
125.
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093–9. doi:10.​1016/​S0140-6736(98)08468-2.PubMedCrossRef
126.
Macallan DC, McNurlan MA, Milne E, Calder AG, Garlick PJ, Griffin GE. Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr. 1995;61(4):818–26.PubMed
127.
Macallan DC. Wasting in HIV infection and AIDS. J Nutr. 1999;129(1S Suppl.):238S–42S.PubMed
128.
129.
130.
131.
132.
Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W Jr, Lang W, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS. 1991;5(5):519–25.PubMedCrossRef
133.
Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16(8):1119–29.PubMedCrossRef
134.
135.
Famularo G, Moretti S, Marcellini S, Nucera E, De Simone C. CD8 lymphocytes in HIV infection: helpful and harmful. J Clin Lab Immunol. 1997;49(1):15–32.PubMed
136.
Cameron ML, Granger DL, Matthews TJ, Weinberg JB. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J Infect Dis. 1994;170(1):60–7.PubMedCrossRef
137.
Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis. 2003;187(1):26–37. doi:10.​1086/​345957.PubMedCrossRef
138.
Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, Gotch F, et al. Loss of blood CD11c(+) myeloid and CD11c(−) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood. 2001;98(8):2574–6.PubMedCrossRef
139.
Cai Q, Huang XL, Rappocciolo G, Rinaldo CR Jr. Natural killer cell responses in homosexual men with early HIV infection. J Acquir Immune Defic Syndr. 1990;3(7):669–76.PubMed
140.
Apoil PA, Puissant B, Roubinet F, Abbal M, Massip P, Blancher A. FOXP3 mRNA levels are decreased in peripheral blood CD4+ lymphocytes from HIV-positive patients. J Acquir Immune Defic Syndr. 2005;39(4):381–5.PubMedCrossRef
141.
Quinnan GV Jr, Siegel JP, Epstein JS, Manischewitz JF, Barnes S, Wells MA. Mechanisms of T-cell functional deficiency in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;103(5):710–4.PubMedCrossRef
142.
Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP. The supportive role of complement in HIV pathogenesis. Immunol Rev. 2001;180:168–76.PubMedCrossRef
143.
Montefiori DC. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin Immunopathol. 1997;18(3):371–90.PubMedCrossRef
144.
145.
Carne CA, Weller IV, Loveday C, Adler MW. From persistent generalised lymphadenopathy to AIDS: who will progress? Br Med J (Clin Res Ed). 1987;294(6576):868–9.CrossRef
146.
Aboulafia DM, Meneses M, Ginsberg S, Siegel MS, Howard WW, Dezube BJ. Acute myeloid leukemia in patients infected with HIV-1. AIDS. 2002;16(6):865–76.PubMedCrossRef
147.
Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16(8):1155–61.PubMedCrossRef
148.
149.
150.
151.
Freedberg KA, Scharfstein JA, Seage GR 3rd, Losina E, Weinstein MC, Craven DE, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130–6.PubMedCrossRef
152.
153.
Samuel R, Bettiker RL, Suh B. AIDS related opportunistic infections, going but not gone. Arch Pharm Res. 2002;25(3):215–28.PubMedCrossRef
154.
Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J. 2014;32(Suppl. 2):i-KK4. doi:10.​1097/​01.​inf.​0000437856.​09540.​1100006454-201311002-00001.
155.
156.
Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. 1983;90(8):859–73.PubMedCrossRef
157.
158.
159.
160.
Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):192–7. doi:10.​1056/​NEJM198707233170​402.PubMedCrossRef
161.
Kingsley LA, Detels R, Kaslow R, Polk BF, Rinaldo CR Jr, Chmiel J, et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet. 1987;1(8529):345–9.PubMedCrossRef
162.
Marmor M, Friedman-Kien AE, Laubenstein L, Byrum RD, William DC, D’Onofrio S, et al. Risk factors for Kaposi’s sarcoma in homosexual men. Lancet. 1982;1(8281):1083–7.PubMedCrossRef
163.
164.
165.
166.
167.
Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353–62. doi:10.​1038/​ni1536.PubMedCrossRef
168.
Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, Utsugi T, et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity. 2003;19(6):877–89.PubMedCrossRef
169.
Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172(8):4676–80.PubMedCrossRef
170.
Calabrese LH, Estes M, Yen-Lieberman B, Proffitt MR, Tubbs R, Fishleder AJ, et al. Systemic vasculitis in association with human immunodeficiency virus infection. Arthritis Rheum. 1989;32(5):569–76.PubMedCrossRef
171.
Gherardi R, Belec L, Mhiri C, Gray F, Lescs MC, Sobel A, et al. The spectrum of vasculitis in human immunodeficiency virus-infected patients.A clinicopathologic evaluation. Arthritis Rheum. 1993;36(8):1164–74.PubMedCrossRef
172.
Metadata
Title
Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome
Authors
Yan-Mei Huang
Xue-Zhi Hong
Jia-Hua Xu
Jiang-Xi Luo
Han-You Mo
Hai-Lu Zhao
Publication date
01-06-2016
Publisher
Springer US
Published in
Immunologic Research / Issue 3/2016
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-015-8767-5

Other articles of this Issue 3/2016

Immunologic Research 3/2016 Go to the issue

Original Article

Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells

Original Article

The immunosuppressive domain of the transmembrane envelope protein gp41 of HIV-1 binds to human monocytes and B cells

Original Article

Disentangling the effects of tocilizumab on neutrophil survival and function

Original Article

Particular activation phenotype of T cells expressing HLA-DR but not CD38 in GALT from HIV-controllers is associated with immune regulation and delayed progression to AIDS

Original Article

Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network

Original Article

The balance of the immune system between HLA-G and NK cells in unexplained recurrent spontaneous abortion and polymorphisms analysis